Apogee Therapeutics Inc. – Filings and Transcripts

NASDAQ: APGE
Share price (3/27/26): $77.82
Market cap (3/27/26): $5.407 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Fairmount Funds Management LLC

Vanguard Group Inc

Henderson Michael Thomas

News Filter

Material Definitive Agreement, Financial Statements or Exhibits

Announces Positive Phase 2 Part a 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses With Every 3- And 6-Month Dosing in Moderate-To-Severe Atopic Dermatitis

Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Phase 1b Interim Results of Zumilokibart (APG777) in Asthma Demonstrated Rapid and Durable Suppression of FeNO (Key Biomarker of Type 2 Inflammation) Through 16 Weeks for All Patients

Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Correspondence with the SEC